Cargando…
Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
OBJECTIVES: This study was aimed to systematically review published economic studies to determine whether dapagliflozin, a sodium-glucose co-transporter inhibitor, plus standard care therapy (SCT) is cost-effective in heart failure with reduced ejection fraction (HFrEF). METHOD: We searched relevant...
Autores principales: | Mohammadnezhad, Ghader, Azadmehr, Behniya, Mirheidari, Mehdi, Yousefi, Nazila |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714165/ https://www.ncbi.nlm.nih.gov/pubmed/36457018 http://dx.doi.org/10.1186/s12962-022-00396-7 |
Ejemplares similares
-
Large Animal Models of Heart Failure With Reduced Ejection Fraction (HFrEF)
por: Spannbauer, Andreas, et al.
Publicado: (2019) -
A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
por: Reed, Brent N, et al.
Publicado: (2015) -
The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?
por: Docherty, Kieran F, et al.
Publicado: (2022) -
Heart Failure with Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF): The Diagnostic Value of Circulating MicroRNAs
por: Chen, Yei-Tsung, et al.
Publicado: (2019) -
Procalcitonin (PCT) Predicts Worse Outcome in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF)
por: Banach, J., et al.
Publicado: (2018)